Second Sight Medical (NSDQ:EYES) said last week it named John Blake as its new chief financial officer, succeeding Thomas Miller who has held the position since 2014. Before joining Second Sight Medical, Blake acted as finance senior VP at Tyr Pharma, and has held positions with Volcano Corp and BD Biosciences, the company said. Blake worked with […]
Appetite for Acquisition: Stryker CEO Lobo says medical device company is in the hunt | Wall Street Beat
Stryker: Acquisitions helped boost top, bottom lines
Although it posted healthy sales and profit growth last year, Stryker Corp. (NYSE:SYK) was a penny shy of analysts’ forecasts for adjusted earnings per share, which usually sends investors into a selling spree.
But the Kalamazoo, Mich.-based device maker bucked the trend, as Wall Street sent SYK shares up 3.8%, to $54.94, in early-afternoon trading as of about 2 p.m. today.
Stryker posted $8.31 billion in sales for 2011, 13.5% more than the $7.32 billion it brought in during 2010.
Bidding war drove up the price in Stryker deal for Orthovita
More Orthovita shareholders sue over Stryker deal
Hedge fund billionaire puts more skin in med-tech | Funding Roundup
Stock bulletin: Hedge fund billionaire bets big on Orthovita | Funding Roundup
Orthovita shareholders sue to stop $316 million Stryker buyout
Stryker launches tender offer for Orthovita
Stryker CEO MacMillan bullish on the future at analyst meeting
Stryker Corp. (NYSE: SYK ) CEO Stephen MacMillan took time out to tout his company’s resilience at an analyst meeting in New York Wednesday.
MacMillan said the Kalamazoo, Mich.-based orthopedic and medical equipment giant has proven its mettle in tough times, something he said would allow it to continue to perform, despite struggles in the orthopedic industry.
